This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Startup Springboard in partnership with BIO-Europe Spring®
March 18, 2021
Delivered DigitallyCentral European Time

Disulfican Ltd


Disulfican is a University spin-out company established to bring a new cancer therapeutic to clinical trial.  

Our business plan is based on progressing our IMP as an orphan designated therapy for malignant mesothelioma (MM), taking advantage of substantial incentives and assistance for which we are eligible as an autonomous SME.

MM is a relatively rare but devastating tumour that forms in the lining of the organs - eligible for Orphan Designation because  there are no effective treatments.

The market size £537m per annum, Europe and USA only, and growing.

We are seeking £1m new shareholder investment to complete the next stage Business Plan Milestone and thereby substantially increase our Enterprise Value.

Investment will be applied to:
•Toxicology, Dose range finding and Pharmacokinetics Studies for PLGA-DS Orphan Disease Designation
•Further preclinical studies to satisfy EMA regulator
•Build Commercial, Clinical & Drug Development strength in the management team